Want to see HK:0013 full AI Analyst Report?

HUTCHMED (China) (0013) Price & Analysis

Q: What was HUTCHMED (China) Limited’s price range in the past 12 months?

HUTCHMED (China) Limited lowest stock price was HK$15.57 and its highest was HK$29.02 in the past 12 months.

Q: What is HUTCHMED (China) Limited’s market cap?

HUTCHMED (China) Limited’s market cap is HK$15.45B.

Q: When is HUTCHMED (China) Limited’s upcoming earnings report date?

HUTCHMED (China) Limited’s upcoming earnings report date is Mar 04, 2027 which is in 213 days.

Q: How were HUTCHMED (China) Limited’s earnings last quarter?

HUTCHMED (China) Limited released its earnings results on Jul 30, 2026. The company reported HK$0.157 earnings per share for the quarter, missing the consensus estimate of HK$0.227 by -HK$0.071.

Q: Is HUTCHMED (China) Limited overvalued?

According to Wall Street analysts HUTCHMED (China) Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does HUTCHMED (China) Limited pay dividends?

HUTCHMED (China) Limited does not currently pay dividends.

Q: What is HUTCHMED (China) Limited’s EPS estimate?

HUTCHMED (China) Limited’s EPS estimate is 0.33.

Q: How many shares outstanding does HUTCHMED (China) Limited have?

HUTCHMED (China) Limited has 872,335,140 shares outstanding.

Q: What happened to HUTCHMED (China) Limited’s price movement after its last earnings report?

HUTCHMED (China) Limited reported an EPS of HK$0.157 in its last earnings report, missing expectations of HK$0.227. Following the earnings report the stock price went down -0.056%.

Q: Which hedge fund is a major shareholder of HUTCHMED (China) Limited?

Currently, no hedge funds are holding shares in HK:0013

8 Followers

0013 Stock Chart & Stats

HK$17.54

HK$0.12(0.68%)

At close: Jul 27 4:00 PM EDT

HK$17.54

HK$0.12(0.68%)

Day’s Range― - ―

52-Week RangeHK$15.57 - HK$29.02

Previous CloseN/A

Volume1.40M

Average Volume (3M)7.40M

Market Cap

HK$15.45B

Enterprise ValueHK$4.72K

Total Cash (Recent Filing)HK$1.37B

Total Debt (Recent Filing)HK$97.89M

Price to Earnings (P/E)4.2

Beta0.88

Next Earnings

Mar 04, 2027

EPS Estimate

0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.54

Shares Outstanding872,335,140

10 Day Avg. Volume5,279,510

30 Day Avg. Volume7,396,099

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.88

Price to Sales (P/S)4.24

P/FCF Ratio-29.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$29.41

Price Target Upside67.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)0.04

Revenue Forecast (FY)HK$626.43M

Bulls Say, Bears Say

Bulls Say

Cash PositionThe company's strong cash position of US$1.37bn offers strategic flexibility for growth opportunities like potential mergers and acquisitions.

Drug ExpansionIndication expansion for drugs like savolitinib and fruquintinib is expected to drive future growth, with promising trial results supporting global regulatory filings.

Bears Say

Revenue GuidanceFull-year revenue guidance for oncology/immunology products has been lowered due to challenges in overseas sales and continuous marketing competition in China.

Sales CompetitionProduct sales in China are under pressure due to competition, with significant declines in revenue from key products.

HUTCHMED (China) News

Hutchmed price target lowered to $14 from $16 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Hutchmed (HCM) to $14 from $16 and keeps a Neutral...

11d ago

HCM

Hutchmed price target lowered to $17 from $20 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $17 from $20 and keeps...

26d ago

HCM

HUTCHMED’s China Rebound and Global FRUZAQLA Push Power 2026 Interim Results

HUTCHMED (China) ( ($HK:0013) ) has provided an announcement. HUTCHMED reported strong interim results for the first half...

4d ago

Hutchmed announces China NMPA approval for Orpathys NDA

Hutchmed (HCM) announced that the new drug application, or NDA, for Orpathys has been granted conditional approval by...

1M ago

HCM

HUTCHMED Wins China Nod for ORPATHYS in MET-Amplified Gastric Cancer

An update from HUTCHMED (China) ( ($HK:0013) ) is now available. HUTCHMED has secured conditional approval from China’s...

1M ago

HUTCHMED Sets Date for 2026 Half-Year Results and Global Investor Webcasts

HUTCHMED (China) ( ($HK:0013) ) has provided an update. HUTCHMED (China) Limited, a commercial-stage biopharmaceutical company specializing in...

1M ago

HUTCHMED Expands Share Option Capacity in Latest Blocklisting Update

HUTCHMED (China) ( ($HK:0013) ) has shared an announcement. HUTCHMED has reported its latest six-month blocklisting return covering...

1M ago

HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma

HUTCHMED (China) ( ($HK:0013) ) has shared an update. HUTCHMED reported pivotal Phase II data for its FGFR1/2/3...

1M ago

HUTCHMED’s sovleplenib posts strong Phase III data in rare autoimmune anemia

HUTCHMED (China) ( ($HK:0013) ) has issued an announcement. HUTCHMED reported positive Phase III results from its ESLIM-02...

2M ago

HUTCHMED Secures New AIM Block Admission for 2026 Share Option Scheme

HUTCHMED (China) ( ($HK:0013) ) has provided an announcement. HUTCHMED has applied to the London Stock Exchange for...

2M ago

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

Morgan Stanley upgraded Hutchmed (HCM) to Equal Weight from Underweight with a price target of $13.60, down from...

2M ago

HCM

HUTCHMED Showcases Broad Oncology Pipeline With New Data at 2026 ASCO Meeting

HUTCHMED (China) ( ($HK:0013) ) has issued an announcement. HUTCHMED will showcase new and updated clinical data for...

2M ago

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

Hutchmed (HCM) and Innovent Biologics jointly announce that the New Drug Application for the combination of Elunate and...

2M ago

HCM

Hutchmed, Innovent Biologics announce China NMPA approval for NDA

Innovent Biologics and Hutchmed (HCM) jointly announce that the new drug application for the combination of Tyvyt and...

2M ago

HCM

0013 FAQ

What was HUTCHMED (China) Limited’s price range in the past 12 months?

HUTCHMED (China) Limited lowest stock price was HK$15.57 and its highest was HK$29.02 in the past 12 months.

What is HUTCHMED (China) Limited’s market cap?

HUTCHMED (China) Limited’s market cap is HK$15.45B.

When is HUTCHMED (China) Limited’s upcoming earnings report date?

HUTCHMED (China) Limited’s upcoming earnings report date is Mar 04, 2027 which is in 213 days.

How were HUTCHMED (China) Limited’s earnings last quarter?

HUTCHMED (China) Limited released its earnings results on Jul 30, 2026. The company reported HK$0.157 earnings per share for the quarter, missing the consensus estimate of HK$0.227 by -HK$0.071.

Is HUTCHMED (China) Limited overvalued?

According to Wall Street analysts HUTCHMED (China) Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does HUTCHMED (China) Limited pay dividends?

HUTCHMED (China) Limited does not currently pay dividends.

What is HUTCHMED (China) Limited’s EPS estimate?

HUTCHMED (China) Limited’s EPS estimate is 0.33.

How many shares outstanding does HUTCHMED (China) Limited have?

HUTCHMED (China) Limited has 872,335,140 shares outstanding.

What happened to HUTCHMED (China) Limited’s price movement after its last earnings report?

HUTCHMED (China) Limited reported an EPS of HK$0.157 in its last earnings report, missing expectations of HK$0.227. Following the earnings report the stock price went down -0.056%.

Which hedge fund is a major shareholder of HUTCHMED (China) Limited?

Currently, no hedge funds are holding shares in HK:0013

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HUTCHMED (China) Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

0.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HUTCHMED (China) Limited

HUTCHMED (China) Limited (HKEX: 0013) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company conducts drug R&D and runs commercial operations to market approved prescription medicines, primarily in China, and works with global partners to develop and commercialize certain assets outside its direct commercial footprint.

HUTCHMED (China) (0013) Earnings & Revenues

Historic Earnings Reports

0013 Stock 12 Month Forecast

Average Price Target

HK$29.41

▲(67.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"HK$15","20":"HK$20","25":"HK$25","30":"HK$30","35":"HK$35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$34.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.406666666666663,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$29.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$21.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,20,25,30,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,18.970769230769232,20.231538461538463,21.492307692307694,22.753076923076925,24.013846153846156,25.274615384615387,26.535384615384615,27.79615384615385,29.056923076923077,30.31769230769231,31.57846153846154,32.83923076923077,{"y":34.1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,18.60974358974359,19.50948717948718,20.409230769230767,21.308974358974357,22.208717948717947,23.108461538461537,24.008205128205127,24.907948717948717,25.807692307692307,26.707435897435893,27.607179487179486,28.506923076923073,{"y":29.406666666666663,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,17.986153846153847,18.262307692307694,18.53846153846154,18.814615384615387,19.090769230769233,19.36692307692308,19.643076923076922,19.91923076923077,20.195384615384615,20.47153846153846,20.747692307692308,21.023846153846154,{"y":21.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >